JP2013526525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013526525A5 JP2013526525A5 JP2013510219A JP2013510219A JP2013526525A5 JP 2013526525 A5 JP2013526525 A5 JP 2013526525A5 JP 2013510219 A JP2013510219 A JP 2013510219A JP 2013510219 A JP2013510219 A JP 2013510219A JP 2013526525 A5 JP2013526525 A5 JP 2013526525A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- pharmaceutical composition
- composition according
- isoindol
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 45
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 15
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 12
- 229960002756 Azacitidine Drugs 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 208000009527 Refractory Anemia Diseases 0.000 claims 6
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 6
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims 4
- 229960005280 Isotretinoin Drugs 0.000 claims 4
- 108010008165 Etanercept Proteins 0.000 claims 3
- 229960003297 Gemtuzumab ozogamicin Drugs 0.000 claims 3
- 229960000403 etanercept Drugs 0.000 claims 3
- 102100006400 CSF2 Human genes 0.000 claims 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960003957 Dexamethasone Drugs 0.000 claims 2
- 101700084039 EPO Proteins 0.000 claims 2
- 101710042422 EPX Proteins 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100018758 IL3 Human genes 0.000 claims 2
- 108020001267 IL3 Proteins 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 108010053490 Infliximab Proteins 0.000 claims 2
- 102000003810 Interleukin-18 Human genes 0.000 claims 2
- 108090000171 Interleukin-18 Proteins 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- 208000000214 Leukemia, Myelomonocytic, Chronic Diseases 0.000 claims 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims 2
- 229960001476 Pentoxifylline Drugs 0.000 claims 2
- 102100002607 TIMP1 Human genes 0.000 claims 2
- 101700040544 TIMP1 Proteins 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- 229960003048 Vinblastine Drugs 0.000 claims 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000003115 biocidal Effects 0.000 claims 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims 2
- 229960003405 ciprofloxacin Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 230000011132 hemopoiesis Effects 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229960000598 infliximab Drugs 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 239000003207 proteasome inhibitor Substances 0.000 claims 2
- 230000036633 rest Effects 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- -1 4-amino-1-oxo-1,3-dihydro-isoindol-2-yl Chemical group 0.000 claims 1
- 210000002397 Granulocyte Precursor Cells Anatomy 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 230000001861 immunosuppresant Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000001167 myeloblast Anatomy 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000004083 survival Effects 0.000 claims 1
Claims (37)
- 3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオン又はその医薬として許容し得る塩を含む、患者の骨髄異形成症候群を治療するための医薬組成物であって、3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオン又はその医薬として許容し得る塩が、5-アザシチジンと共投与されるように用いられることを特徴とする、前記医薬組成物。
- 前記骨髄異形成症候群が、不応性貧血、環状鉄芽球性不応性貧血、芽球増加型不応性貧血、移行期芽球増加型不応性貧血、又は慢性骨髄単球性白血病である、請求項1記載の医薬組成物。
- 前記骨髄異形成症候群が、国際予後判定システム(IPSS)において、中間リスク2又は高リスクである、請求項1記載の医薬組成物。
- 3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオン又はその医薬として許容し得る塩が、少なくとも1種の追加活性薬と共投与されるように用いられることを特徴とする、請求項1記載の医薬組成物。
- 前記追加活性薬が、血液細胞形成を改善することが可能である、請求項4記載の医薬組成物。
- 前記追加活性薬が、サイトカイン、造血成長因子、抗癌剤、抗生物質、プロテアソーム阻害剤、又は免疫抑制薬である、請求項4記載の医薬組成物。
- 前記追加活性薬が、ゲムツズマブ・オゾガマイシン、エタネルセプト、イマチニブ、抗-TNF-α抗体、インフリキシマブ、G-CSF、GM-CSF、EPO、トポテカン、ペントキシフィリン、シプロフロキサシン、イリノテカン、ビンブラスチン、デキサメタゾン、IL2、IL8、IL18、Ara-C、ビノレルビン、イソトレチノイン、13-cis-レチノイン酸、又はそれらの医薬として活性のある変異体若しくは誘導体である、請求項4記載の医薬組成物。
- 前記患者が、Del5q31-33異常を有する、請求項1記載の医薬組成物。
- 前記骨髄異形成症候群が、原発性又は続発性である、請求項1記載の医薬組成物。
- 前記5-アザシチジンが、皮下、静脈内、又は経口投与されるように用いられることを特徴とする、請求項1記載の医薬組成物。
- 前記3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオンが、経口投与されるように用いられることを特徴とする、請求項1記載の医薬組成物。
- 前記5-アザシチジンが、28日毎に、1日目から7日目まで、約25mg/m2/日〜約75mg/m2/日の量で皮下投与されるように用いられることを特徴とする、請求項1記載の医薬組成物。
- 前記5-アザシチジンが、28日毎に、1日目から5日目まで、約25mg/m2/日〜約75mg/m2/日の量で皮下投与されるように用いられることを特徴とする、請求項1記載の医薬組成物。
- 前記5-アザシチジンが、28日毎に、1日目から7日目まで、120mg/日の量で経口投与されるように用いられることを特徴とする、請求項1記載の医薬組成物。
- 前記3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオンが、約5mg〜約25mg/日の量で投与され、それに休薬期間が続くサイクルで投与されるように用いられることを特徴とする、請求項1記載の医薬組成物。
- 前記3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオンが、28日毎に、約10mg/日の量で21日間経口投与され、それに7日間の休薬が続くように用いられることを特徴とする、請求項1記載の医薬組成物。
- 前記3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオンが、28日毎に、約5mg〜約25mg/日の量で21日間経口投与され、それに7日間の休薬が続くように用いられることを特徴とする、請求項12、13又は14記載の医薬組成物。
- 3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオン又はその医薬として許容し得る塩を含む、骨髄異形成症候群の比較的高いリスクを有する患者の生存を改善するための医薬組成物であって、3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオン又はその医薬として許容し得る塩が、5-アザシチジンと共投与されるように用いられることを特徴とする、前記医薬組成物。
- 前記比較的高いリスクの骨髄異形成症候群が、国際予後判定システム(IPSS)において中間リスク2若しくは高リスクであるか、又は芽球増加型不応性貧血、移行期芽球増加型不応性貧血、若しくは10〜29%の骨髄芽球を有する慢性骨髄単球性白血病である、請求項18記載の医薬組成物。
- 前記5-アザシチジンが、皮下、静脈内、又は経口投与されるように用いられることを特徴とする、請求項18記載の医薬組成物。
- 前記3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオンが、経口投与されるように用いられることを特徴とする、請求項18記載の医薬組成物。
- 前記5-アザシチジンが、28日毎に、1日目から7日目まで、約25mg/m2/日〜約75mg/m2/日の量で皮下投与されるように用いられることを特徴とする、請求項18記載の医薬組成物。
- 前記5-アザシチジンが、28日毎に、1日目から5日目まで、約25mg/m2/日〜約75mg/m2/日の量で皮下投与されるように用いられることを特徴とする、請求項18記載の医薬組成物。
- 前記5-アザシチジンが、28日毎に、1日目から7日目まで、120mg/日の量で経口投与されるように用いられることを特徴とする、請求項18記載の医薬組成物。
- 前記3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオンが、約5mg〜約25mg/日の量で投与され、それに休薬期間が続くサイクルで投与されるように用いられることを特徴とする、請求項18記載の医薬組成物。
- 前記3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオンが、28日毎に、約10mg/日の量を21日間経口投与され、それに7日間の休薬が続くように用いられることを特徴とする、請求項18記載の医薬組成物。
- 前記3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオンが、28日毎に、約5mg〜約25mg/日の量で21日間経口投与され、それに7日間の休薬が続くように用いられることを特徴とする、請求項22、23又は24記載の医薬組成物。
- 3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオン又はその医薬として許容し得る塩が、少なくとも1種の追加活性薬と共投与されるように用いられることを特徴とする、請求項18記載の医薬組成物。
- 前記追加活性薬が、血液細胞形成を改善することが可能である、請求項28記載の医薬組成物。
- 前記追加活性薬が、サイトカイン、造血成長因子、抗癌剤、抗生物質、プロテアソーム阻害剤、又は免疫抑制薬である、請求項28記載の医薬組成物。
- 前記追加活性薬が、ゲムツズマブ・オゾガマイシン、エタネルセプト、イマチニブ、抗-TNF-α抗体、インフリキシマブ、G-CSF、GM-CSF、EPO、トポテカン、ペントキシフィリン、シプロフロキサシン、イリノテカン、ビンブラスチン、デキサメタゾン、IL2、IL8、IL18、Ara-C、ビノレルビン、イソトレチノイン、13-cis-レチノイン酸、又はそれらの医薬として活性のある変異体若しくは誘導体、又はそれらの組み合わせである、請求項28記載の医薬組成物。
- 前記追加活性薬が、ゲムツズマブ・オゾガマイシンである、請求項4又は28記載の医薬組成物。
- 前記追加活性薬が、エタネルセプトである、請求項4又は28記載の医薬組成物。
- 前記5-アザシチジンが、28日毎に、1日目から5日目まで、約75mg/m2/日の量で皮下投与されるように用いられることを特徴とする、請求項1又は18記載の医薬組成物。
- 前記5-アザシチジンが、28日毎に、1日目から5日目まで及び8日目から12日目まで、約50mg/m2/日の量で皮下投与されるように用いられることを特徴とする、請求項1又は18記載の医薬組成物。
- 前記3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオンが、28日毎に、1日目から14日目まで、約5mg〜約10mg/日の量で経口投与されるように用いられることを特徴とする、請求項1又は18記載の医薬組成物。
- 前記3-(4-アミノ-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル)-ピペリジン-2,6-ジオンが、28日毎に、1日目から21日目まで、約5mg〜約10mg/日の量で経口投与されるように用いられることを特徴とする、請求項1又は18記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/777,765 US8404716B2 (en) | 2002-10-15 | 2010-05-11 | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US12/777,765 | 2010-05-11 | ||
PCT/US2011/035822 WO2011143147A1 (en) | 2010-05-11 | 2011-05-10 | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013526525A JP2013526525A (ja) | 2013-06-24 |
JP2013526525A5 true JP2013526525A5 (ja) | 2014-04-17 |
Family
ID=44314968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013510219A Pending JP2013526525A (ja) | 2010-05-11 | 2011-05-10 | レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法 |
Country Status (6)
Country | Link |
---|---|
US (4) | US8404716B2 (ja) |
EP (2) | EP2568983A1 (ja) |
JP (1) | JP2013526525A (ja) |
CN (1) | CN103025330A (ja) |
AU (1) | AU2011253161B2 (ja) |
WO (1) | WO2011143147A1 (ja) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US8404717B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US8404716B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
BR112013021562B1 (pt) | 2011-03-16 | 2023-01-10 | Argenx Bvba | Anticorpos para cd70 |
MX2014003591A (es) * | 2011-09-26 | 2014-09-08 | Celgene Corp | Terapia de combinacion para canceres quimiorresistentes. |
MX370567B (es) | 2012-05-09 | 2019-12-17 | Cantex Pharmaceuticals Inc | Tratamiento de mielosupresion. |
US10532050B2 (en) | 2013-04-09 | 2020-01-14 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
CN106572989B (zh) * | 2014-07-24 | 2021-08-27 | H·李·莫菲特癌症中心与研究所公司 | 用于治疗骨髓增生异常综合征的蛋白磷酸酶2a抑制剂 |
AU2015305449B2 (en) | 2014-08-22 | 2021-05-06 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
US10052346B2 (en) * | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
EP3442584B1 (en) | 2016-03-15 | 2021-07-28 | Seagen Inc. | Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors |
WO2017180768A1 (en) * | 2016-04-15 | 2017-10-19 | Seattle Genetics, Inc. | Combinations of cd33 antibody drug conjugates with hypomethylating agents |
US11110179B2 (en) | 2016-06-03 | 2021-09-07 | Seagen Inc. | Combination of CD33 antibody drug conjugates with chemotherapeutic agents |
EA201892746A1 (ru) | 2016-06-06 | 2019-06-28 | Селджин Корпорейшн | Лечение гематологической злокачественной опухоли с помощью 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида |
US11191771B2 (en) | 2016-06-09 | 2021-12-07 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors |
CA3049435A1 (en) | 2017-01-09 | 2018-07-12 | Scott Grindrod | Selective histone deacetylase inhibitors for the treatment of human disease |
US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
US11407723B2 (en) | 2018-01-09 | 2022-08-09 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
EP3749298B1 (en) | 2018-02-07 | 2023-04-05 | Lovelace Biomedical Research Institute | Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer |
WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
US20210222228A1 (en) * | 2018-08-26 | 2021-07-22 | Cardiff Oncology, Inc. | Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitors |
WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
JP2022511746A (ja) * | 2018-11-30 | 2022-02-01 | エムイーアイ ファーマ,インク. | 高リスクの、および非常に高リスクのmdsのための併用療法 |
TW202038958A (zh) | 2018-12-18 | 2020-11-01 | 比利時商阿根思公司 | Cd70組合治療 |
EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
CN109771643A (zh) * | 2019-03-06 | 2019-05-21 | 厦门大学附属中山医院 | 儿童地中海贫血干细胞移植预处理联合化疗剂 |
EP3935050A4 (en) | 2019-03-06 | 2023-01-04 | C4 Therapeutics, Inc. | HETEROCYCLIC COMPOUNDS FOR MEDICAL TREATMENT |
US11197852B2 (en) * | 2019-04-22 | 2021-12-14 | Starton Therapeutics, Inc. | Continuous delivery of lenalidomide and other immunomodulatory agents |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3228601A (en) | 1964-02-20 | 1966-01-11 | Monarch Marking Systems Inc | Controls for marking machine |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4551177A (en) | 1984-04-23 | 1985-11-05 | National Starch And Chemical Corporation | Compressible starches as binders for tablets or capsules |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US5974203A (en) | 1988-04-11 | 1999-10-26 | Canon Kabushiki Kaisha | Pattern recognition communication apparatus for transmitting and receiving image data |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5288487A (en) | 1989-02-28 | 1994-02-22 | Morinaga Milk Industry Co., Ltd. | Human monocyte-macrophage-CSF preparations |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5354690A (en) * | 1989-07-07 | 1994-10-11 | Karl Tryggvason | Immunological methods for the detection of the human type IV collagen α5 chain |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
EP0505552A4 (en) | 1990-10-12 | 1994-06-08 | Amgen Inc | Megakaryocyte maturation factors |
WO1992014455A1 (en) | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5358941A (en) | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US20010056114A1 (en) | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5594637A (en) | 1993-05-26 | 1997-01-14 | Base Ten Systems, Inc. | System and method for assessing medical risk |
US5698579A (en) | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5641758A (en) | 1993-11-10 | 1997-06-24 | Kluge; Michael | Cytarabine derivatives, the preparation and use thereof |
US6432924B1 (en) | 1993-12-26 | 2002-08-13 | East Carolina University | Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase |
GB9412394D0 (en) | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
AU3972295A (en) | 1994-10-28 | 1996-05-23 | Advanced Health Med-E-Systems Corporation | Prescription management system |
US5593696A (en) | 1994-11-21 | 1997-01-14 | Mcneil-Ppc, Inc. | Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders |
US5619991A (en) | 1995-04-26 | 1997-04-15 | Lucent Technologies Inc. | Delivery of medical services using electronic data communications |
US5731325A (en) | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
US5643915A (en) | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
US5832449A (en) | 1995-11-13 | 1998-11-03 | Cunningham; David W. | Method and system for dispensing, tracking and managing pharmaceutical trial products |
US6063026A (en) | 1995-12-07 | 2000-05-16 | Carbon Based Corporation | Medical diagnostic analysis system |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
ATE229521T3 (de) | 1996-07-24 | 2002-12-15 | Celgene Corp | Substituierte 2-(2,6-dioxopiperidin-3-yl)- phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US5798368A (en) | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5929117A (en) | 1996-08-12 | 1999-07-27 | Celgene Corporation | Immunotherapeutic agents |
US5924074A (en) | 1996-09-27 | 1999-07-13 | Azron Incorporated | Electronic medical records system |
PT1920773E (pt) | 1996-11-05 | 2011-01-27 | Childrens Medical Center | Composições para a inibição de angiogénese |
US6131090A (en) | 1997-03-04 | 2000-10-10 | Pitney Bowes Inc. | Method and system for providing controlled access to information stored on a portable recording medium |
EP0998271B3 (en) | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
WO1999010829A1 (en) | 1997-08-22 | 1999-03-04 | Deka Products Limited Partnership | Health care system and method for physician order entry |
US5955476A (en) | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
US5874448A (en) | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
US6096757A (en) | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
TR200101500T2 (tr) | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı. |
JPH11286455A (ja) | 1998-03-31 | 1999-10-19 | Kanebo Ltd | 骨髄異形成症候群治療薬 |
US6673828B1 (en) | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
US6045501A (en) | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
GB9904585D0 (en) | 1999-02-26 | 1999-04-21 | Gemini Research Limited | Clinical and diagnostic database |
ATE306469T1 (de) | 1999-03-18 | 2005-10-15 | Celgene Corp | Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine |
US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
AU6015400A (en) | 1999-07-16 | 2001-02-05 | Amato Pharmaceutical Products, Ltd. | Glycyrrhizin preparations for transmucosal absorption |
US6202923B1 (en) | 1999-08-23 | 2001-03-20 | Innovation Associates, Inc. | Automated pharmacy |
US6878733B1 (en) | 1999-11-24 | 2005-04-12 | Sugen, Inc. | Formulations for pharmaceutical agents ionizable as free acids or free bases |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
JP2003521507A (ja) | 2000-02-04 | 2003-07-15 | ディポメド,インコーポレイティド | ゼロ次薬物放出に接近するシェル−コア剤形 |
AU2001249755A1 (en) | 2000-03-31 | 2001-10-15 | Celgene Corporation | Inhibition of cyclooxygenase-2 activity |
NZ522766A (en) | 2000-05-15 | 2005-09-30 | Celgene Corp | Compositions and methods for the treatment of colorectal cancer with irinotecan and thalidomide to reduce side effects |
CA2408707C (en) | 2000-05-15 | 2010-04-13 | Celgene Corp. | Compositions and methods for the treatment of cancer |
WO2002015926A1 (fr) | 2000-08-24 | 2002-02-28 | Kirin Beer Kabushiki Kaisha | Compositions medicinales contenant des ligands c-mpl, destinees a l'augmentation des plaquettes et des erythrocytes |
US6315720B1 (en) | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
ES2290091T3 (es) | 2000-11-30 | 2008-02-16 | The Children's Medical Center Corporation | Sintesis de enantiomeros de 4-amino-talidomida. |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
GB0102342D0 (en) | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
WO2002068414A2 (en) | 2001-02-27 | 2002-09-06 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
DE60231989D1 (de) | 2001-08-06 | 2009-05-28 | Childrens Medical Center | Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga |
US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
JP4027693B2 (ja) | 2002-03-20 | 2007-12-26 | トリニティ工業株式会社 | 塗料送給装置及びバルブユニット |
US20030220254A1 (en) | 2002-03-29 | 2003-11-27 | Texas Tech University System | Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
EP1505973B1 (en) | 2002-05-17 | 2010-03-03 | Celgene Corporation | Combinations for treating multiple myeloma |
EP2258363A1 (en) | 2002-05-17 | 2010-12-08 | Celgene Corporation | Compositions for treatment of cancers |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US8404717B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
EP1556010A4 (en) | 2002-10-31 | 2007-12-05 | Supergen Inc | PHARMACEUTICAL FORMULATIONS TARGETING SPECIFIC REGIONS OF THE GASTROINTESTINAL TRACT |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US20040152632A1 (en) | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
US6943249B2 (en) | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
CN1968695A (zh) | 2004-04-14 | 2007-05-23 | 细胞基因公司 | 含有用于治疗和控制骨髓发育不良综合征的免疫调节化合物的组合物和使用方法 |
WO2005110085A2 (en) | 2004-04-14 | 2005-11-24 | Celgene Corporation | Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
US20060128654A1 (en) | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
US20070155791A1 (en) | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
US8058260B2 (en) | 2006-05-22 | 2011-11-15 | Xenoport, Inc. | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof |
US8664272B2 (en) | 2006-08-30 | 2014-03-04 | Temple University—Of the Commonwealth System of Higher Education | Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
WO2008028193A2 (en) * | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain vehicles, installations and methods |
WO2009058394A1 (en) | 2007-11-01 | 2009-05-07 | Celgene Corporation | Cytidine analogs for treatment of myelodysplastic syndromes |
PL3692983T3 (pl) | 2008-05-15 | 2021-12-27 | Celgene Corporation | Doustne formulacje analogów cytydyny i sposoby ich zastosowania |
BRPI1007855B1 (pt) | 2009-05-19 | 2020-03-10 | Celgene Corporation | Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona |
US9713375B1 (en) | 2015-02-26 | 2017-07-25 | Brett Einar Rahm | Collapsible portable table |
-
2010
- 2010-05-11 US US12/777,765 patent/US8404716B2/en not_active Expired - Lifetime
-
2011
- 2011-05-10 CN CN2011800341566A patent/CN103025330A/zh active Pending
- 2011-05-10 AU AU2011253161A patent/AU2011253161B2/en active Active
- 2011-05-10 EP EP11731546A patent/EP2568983A1/en not_active Withdrawn
- 2011-05-10 EP EP17154180.8A patent/EP3219317A1/en not_active Withdrawn
- 2011-05-10 WO PCT/US2011/035822 patent/WO2011143147A1/en active Application Filing
- 2011-05-10 JP JP2013510219A patent/JP2013526525A/ja active Pending
-
2013
- 2013-03-13 US US13/801,262 patent/US9056120B2/en not_active Expired - Lifetime
-
2014
- 2014-10-17 US US14/517,280 patent/US9925207B2/en not_active Expired - Lifetime
-
2018
- 2018-03-20 US US15/926,740 patent/US20180207185A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2013526525A5 (ja) | ||
JP2009545600A5 (ja) | ||
Rothenberg | Irinotecan (CPT-11): recent developments and future directions–colorectal cancer and beyond | |
JP2014148535A5 (ja) | ||
JP2014065696A5 (ja) | ||
JP2014040437A5 (ja) | ||
CN107087409A (zh) | 苯并杂环化合物及其应用 | |
JP2006507271A5 (ja) | ||
JP2005530784A5 (ja) | ||
JP2014532704A5 (ja) | ||
JP2009510171A5 (ja) | ||
JP2017524031A5 (ja) | ||
JP2013526525A (ja) | レナリドミド及びアザシチジン併用療法による骨髄異形成症候群の治療方法 | |
JP2012180381A5 (ja) | ||
JP2012067116A5 (ja) | ||
JP2010520289A5 (ja) | ||
IL168061A (en) | Compound 3 - (4 - amino - 1 - oxo - 1, 3 - dihydro - isoindole - 2 - il) - piperidine - 2, 6 - deion for the use of the drug for the treatment and regulation of myelodysplastic symptoms | |
JP6898329B2 (ja) | 併用療法 | |
CN103458896B (zh) | 用于治疗癌症的方法 | |
JP2009539994A5 (ja) | ||
WO2015034678A3 (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
TWI741286B (zh) | 治療癌症之方法 | |
JP2011500805A5 (ja) | ||
Somers et al. | Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation | |
AU2010333083B2 (en) | 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment |